Part 4/9:
On a more positive note, the CAR-T (Chimeric Antigen Receptor T-cell) therapy developers took center stage at ASCO. These therapies represent a pioneering approach to treating cancer by enhancing the immune system’s ability to target cancer cells.
Notable Companies: Juno Therapeutics and Kite Pharma
Among the highlighted companies were Juno Therapeutics and Kite Pharma. Juno presented several promising data points, with complete responses in up to 91% of patients using its JCAR015 therapy for acute lymphoblastic leukemia (ALL). Similarly, Kite Pharma has also shown promising results in treating this aggressive form of leukemia, sparking considerable investor interest.